|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C11orf24 |
Gene summary for C11ORF24 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C11orf24 | Gene ID | 53838 |
| Gene name | chromosome 11 open reading frame 24 | |
| Gene Alias | DM4E3 | |
| Cytomap | 11q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | E9PRU5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 53838 | C11orf24 | LZE7T | Human | Esophagus | ESCC | 1.76e-05 | 4.63e-01 | 0.0667 |
| 53838 | C11orf24 | LZE8T | Human | Esophagus | ESCC | 8.19e-04 | 1.90e-01 | 0.067 |
| 53838 | C11orf24 | LZE20T | Human | Esophagus | ESCC | 5.74e-15 | 4.02e-01 | 0.0662 |
| 53838 | C11orf24 | LZE22T | Human | Esophagus | ESCC | 1.32e-03 | 4.22e-01 | 0.068 |
| 53838 | C11orf24 | LZE24T | Human | Esophagus | ESCC | 7.02e-13 | 4.35e-01 | 0.0596 |
| 53838 | C11orf24 | LZE6T | Human | Esophagus | ESCC | 5.63e-04 | 3.81e-01 | 0.0845 |
| 53838 | C11orf24 | P1T-E | Human | Esophagus | ESCC | 1.61e-06 | 2.87e-01 | 0.0875 |
| 53838 | C11orf24 | P2T-E | Human | Esophagus | ESCC | 4.55e-24 | 4.74e-01 | 0.1177 |
| 53838 | C11orf24 | P4T-E | Human | Esophagus | ESCC | 1.76e-35 | 9.26e-01 | 0.1323 |
| 53838 | C11orf24 | P5T-E | Human | Esophagus | ESCC | 1.61e-17 | 5.11e-01 | 0.1327 |
| 53838 | C11orf24 | P8T-E | Human | Esophagus | ESCC | 3.32e-19 | 3.57e-01 | 0.0889 |
| 53838 | C11orf24 | P9T-E | Human | Esophagus | ESCC | 2.35e-16 | 4.73e-01 | 0.1131 |
| 53838 | C11orf24 | P10T-E | Human | Esophagus | ESCC | 3.33e-18 | 2.99e-01 | 0.116 |
| 53838 | C11orf24 | P11T-E | Human | Esophagus | ESCC | 6.36e-26 | 8.22e-01 | 0.1426 |
| 53838 | C11orf24 | P12T-E | Human | Esophagus | ESCC | 8.55e-25 | 4.15e-01 | 0.1122 |
| 53838 | C11orf24 | P15T-E | Human | Esophagus | ESCC | 7.78e-24 | 5.52e-01 | 0.1149 |
| 53838 | C11orf24 | P16T-E | Human | Esophagus | ESCC | 3.05e-15 | 3.26e-01 | 0.1153 |
| 53838 | C11orf24 | P17T-E | Human | Esophagus | ESCC | 2.44e-07 | 3.99e-01 | 0.1278 |
| 53838 | C11orf24 | P19T-E | Human | Esophagus | ESCC | 1.13e-25 | 1.46e+00 | 0.1662 |
| 53838 | C11orf24 | P20T-E | Human | Esophagus | ESCC | 1.69e-23 | 5.74e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C11orf24 | SNV | Missense_Mutation | c.26G>C | p.Trp9Ser | p.W9S | Q96F05 | protein_coding | deleterious(0) | benign(0.298) | TCGA-AR-A24N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C11orf24 | SNV | Missense_Mutation | rs758231616 | c.385N>A | p.Ala129Thr | p.A129T | Q96F05 | protein_coding | tolerated(0.13) | possibly_damaging(0.661) | TCGA-B6-A1KN-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| C11orf24 | SNV | Missense_Mutation | novel | c.232N>A | p.Glu78Lys | p.E78K | Q96F05 | protein_coding | tolerated(0.71) | benign(0.019) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| C11orf24 | SNV | Missense_Mutation | novel | c.1087A>G | p.Arg363Gly | p.R363G | Q96F05 | protein_coding | tolerated(0.85) | benign(0.003) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | SD | |
| C11orf24 | SNV | Missense_Mutation | rs756164298 | c.724G>A | p.Ala242Thr | p.A242T | Q96F05 | protein_coding | tolerated(1) | benign(0) | TCGA-OL-A66N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| C11orf24 | insertion | Frame_Shift_Ins | novel | c.551_552insCGCTGAGGCAGAGCTGA | p.His185AlafsTer39 | p.H185Afs*39 | Q96F05 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| C11orf24 | SNV | Missense_Mutation | rs543093269 | c.853G>A | p.Ala285Thr | p.A285T | Q96F05 | protein_coding | tolerated(1) | benign(0) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| C11orf24 | SNV | Missense_Mutation | c.1182G>T | p.Gln394His | p.Q394H | Q96F05 | protein_coding | tolerated(0.15) | benign(0.012) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| C11orf24 | SNV | Missense_Mutation | rs536792763 | c.502G>A | p.Ala168Thr | p.A168T | Q96F05 | protein_coding | tolerated(0.63) | benign(0) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| C11orf24 | SNV | Missense_Mutation | rs756449465 | c.59C>T | p.Ala20Val | p.A20V | Q96F05 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |